A simplified premedication protocol for one-hour paclitaxel infusion in various combinations

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Paclitaxel (Taxol) administration typically involves lengthy infusions (3-24 hours) and complex premedication protocols.
• Optimizing paclitaxel dosing and scheduling is crucial for its effective use in cancer therapy.
• Current administration protocols present challenges for outpatient settings.

Purpose of the Study:

• To simplify paclitaxel administration for practicality in outpatient cancer care.
• To evaluate a shortened one-hour infusion duration for paclitaxel.
• To assess a minimized premedication regimen for paclitaxel administration.

Main Methods:

• A study involving 100 patients with various cancers (NSCLC, SCLC, breast, head and neck, ovarian) receiving paclitaxel-based chemotherapy.
• Patients received paclitaxel at doses of 175 mg/m2 or 225 mg/m2 over a one-hour infusion.
• A simplified premedication regimen included dexamethasone, dimethindene maleate, and ranitidine, followed by standard antiemetics.

Main Results:

• Hypersensitivity reactions occurred in 7.0% of patients, with no significant correlation to patient demographics, disease type, dose, or treatment cycles.
• No serious adverse events were reported during the study.
• The one-hour infusion schedule was well-tolerated across different cancer types and paclitaxel doses.

Conclusions:

• The simplified one-hour paclitaxel administration schedule is a safe and viable option for outpatient cancer treatment.
• This shortened schedule is compatible with combination chemotherapy regimens, including those with ifosfamide, platinum compounds, or epirubicin.
• The study supports the adoption of this streamlined approach to improve patient convenience and treatment accessibility.